Published in Cancer Weekly, October 8th, 2002
Modrenal is a refractory breast cancer treatment, which will be used in cases where front line treatment has failed to halt, or in some cases speeded up, the rate of cancer growth.
In clinical trials, Modrenal has proved 46% effective as a second line oncology treatment. The drug now has a U.K. license and should be available to U.K. cancer sufferers this year.
Modrenal harnesses new thinking on hormone sensitive cancers. Historically, scientists have worked on the theory that one alpha receptor controls and blocks the flow...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.